neoag
Neoantigen × AI
Daily research signal
TOPICS / TUMOR TYPE

Lung cancer (NSCLC)

Non-small-cell lung cancer — a high-incidence, often high-TMB setting for neoantigen vaccines combined with checkpoint blockade.

Topic6 items2026-06-22 – 2026-07-06
Tumor types
Melanoma58Glioblastoma9Liver cancer (HCC)6Lung cancer (NSCLC)6Head & neck cancer5Colorectal cancer5Pancreatic cancer5Breast cancer4Kidney cancer (RCC)2Ovarian cancer2Gastric cancer1Lynch syndrome1
01
Clinical

Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has registered a Phase 1 study evaluating personalized cancer vaccines alone and in combination with toripalimab for patients with resected non-small cell lung cancer (NSCLC). The trial features dose escalation and expansion phases to assess safety, tolerability, immunogenicity, and preliminary anti-tumor activity. This represents an early-stage clinical test of combining neoantigen-specific vaccination with checkpoint inhibition in a post-surgical setting.

clinicaltrials · brief 2026-07-06 · published 2026-07-06
02
Commercial

Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC - Slideshow (OTCMKTS:TRGNF) 2026-07-01 - Seeking Alpha

Transgene SA is expanding its pipeline of individualized neoantigen therapeutic vaccines into early-stage non-small cell lung cancer (NSCLC). The company’s recent updates highlight progress in developing personalized immunotherapies beyond their current indications, signaling an effort to diversify the application of their neoantigen platform across major oncology markets.

Transgene
news · brief 2026-07-01 · published 2026-07-01
04
Commercial

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine - marketscreener.com

Transgene has announced the expansion of its myvac® platform into NSCLC via TG4070, an individualized neoantigen therapeutic vaccine. The company is leveraging its proprietary technology to target personalized antigens in this major solid tumor indication, marking a strategic broadening of its commercial pipeline beyond previous indications.

Transgene
news · brief 2026-06-22 · published 2026-06-22
05
Commercial

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine - The Manila Times

Reports confirm Transgene's entry of TG4070 into the NSCLC market as part of its myvac® portfolio. By targeting individualized neoantigens, Transgene aims to capitalize on the growing commercial interest in personalized cancer vaccines, positioning TG4070 as a key asset in its expanding therapeutic lineup.

Transgene
news · brief 2026-06-22 · published 2026-06-22
06
Commercial

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic - Boursorama

Transgene is advancing TG4070, an individualized neoantigen vaccine under its myvac® platform, into non-small cell lung cancer. This development highlights the company's strategy to apply its personalized vaccine technology across multiple solid tumor types, though no specific trial phases or efficacy outcomes were disclosed in the current reports.

Transgene
news · brief 2026-06-22 · published 2026-06-22
Where nextAll topicsToday’s briefTrials tracker